Related Experiment Videos
Lymphocyte migratory pathways in adjuvant disease. II. Distribution of thoracic duct lymph-borne immunoblasts
Evidence for enhanced extravasation of thoracic duct lymph-borne immuno-blasts within joints of rats during the onset of adjuvant disease was sought by adoptive transfer of cells radiolabeled with (125I)-iodo-2-deoxyuridine. Migratory behavior of cells from normal or adjuvant disease donors, during both inductive and overt stages of the disease process, was contrasted in normal and adjuvant disease recipients. The results provided no evidence to indicate enhanced joint-seeking properties of lymph-borne immuno-blasts obtained from adjuvant disease donors, either during the period preceding overt joint involvement or during the phase of chronic inflammation. The ability of lymph-borne cells to passively transfer the disease thus appears more likely due to systemic actions of these cells, mediators produced by them, or concomitantly passaged antigen upon patterns of inflammatory cell mobilization and/or vascular endothelial cell activation.
Evidence for enhanced extravasation of thoracic duct lymph-borne immuno-blasts within joints of rats during the onset of adjuvant disease was sought by adoptive transfer of cells radiolabeled with (125I)-iodo-2-deoxyuridine. Migratory behavior of cells from normal or adjuvant disease donors, during both inductive and overt stages of the disease process, was contrasted in normal and adjuvant disease recipients. The results provided no evidence to indicate enhanced joint-seeking properties of lymph-borne immuno-blasts obtained from adjuvant disease donors, either during the period preceding overt joint involvement or during the phase of chronic inflammation. The ability of lymph-borne cells to passively transfer the disease thus appears more likely due to systemic actions of these cells, mediators produced by them, or concomitantly passaged antigen upon patterns of inflammatory cell mobilization and/or vascular endothelial cell activation.